Company Description
Upexi, Inc., a brand owner, engages in the development, manufacture, and distribution of consumer products.
It offers nail grinder and healthy all-natural pet supplements under the LuckyTail brand; energy solutions under the PRAX brand; functional mushrooms under the Cure Mushrooms brand; craft cannabinoid under the Moonwlkr brand; and gummies and other products under the Gumi Labs brand.
The company sells its products through direct-to-consumer network, wholesale partnerships, and third-party platform.
It also focuses on cryptocurrency industry and cash management of assets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022.
The company was incorporated in 2018 and is headquartered in Tampa, Florida.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 24, 2021 |
| Industry | Internet Content & Information |
| Sector | Communication Services |
| Employees | 64 |
| CEO | Allan Marshall |
Contact Details
Address: 3030 North Rocky Point Drive, Suite 420 Tampa, Florida 33607 United States | |
| Phone | 701 353 5425 |
| Website | upexi.com |
Stock Details
| Ticker Symbol | UPXI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001775194 |
| CUSIP Number | 39959A106 |
| ISIN Number | US39959A1060 |
| Employer ID | 83-3378978 |
| SIC Code | 6199 |
Key Executives
| Name | Position |
|---|---|
| Allan J. Marshall | Chief Executive Officer, President and Chairman of the Board |
| Brian Benjamin Rudick C.F.A. | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | SCHEDULE 13G/A | Filing |
| Aug 11, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 8, 2025 | 8-K | Current Report |
| Aug 8, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 8, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 5, 2025 | SCHEDULE 13G/A | Filing |
| Aug 1, 2025 | 8-K | Current Report |
| Jul 30, 2025 | SCHEDULE 13G | Filing |
| Jul 29, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 29, 2025 | D | Notice of Exempt Offering of Securities |